Published : 15 Apr 2017

---

Aagami announces a new client win. Aagami has received a mandate for strategic advisory and cross border licensing partnering.

The  UK based client's proprietary nanotechnology drug delivery platform is based on a specialist formulation of silicon that enhances drug bioavailability and therapeutic compliance through optimized solubility, stability and controlled therapeutic drug release. The particle contains hundreds of channels (mesopores) in a honeycomb porous structure to facilitate this. They are made from FDA GRAS approved materials. It is claimed to be the Best Drug Delivery Solution Available Today, that also  works with multiple forms such as topical, oral and injectable.

Aagami looks forward to bringing success to its new client.